To evaluate effect on comorbid disease and weight loss in the long-term (\>five years) after Roux-en-Y gastric bypass (RYGB) surgery for severe obesity.
Individuals with severe obesity frequently have comorbid diseases, e.g. diabetes, hypertension, hyperlipidemia, and sleep apnea. We will study the remission rate and weight loss in the long-term (10 years) after Roux-en-Y gastric bypass (RYGB) surgery in a nationwide large group of patients.
Study Type
OBSERVATIONAL
Enrollment
25,000
Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
Uppsala University
Uppsala, Sweden
RECRUITINGChange in comorbid conditions, as defined by use of pharmacological treatment
Remission of diabetes mellitus, hypertension, dyslipidemia, and depression as defined by use of pharmacological treatment, and sleep apnea as defined by use of CPAP. Data will be collected from SOReg.
Time frame: 10 years
Number of patients with pathological laboratory data (corresponding to the studied comorbid conditions)
Glucose, HbA1c, LDL, HDL, triglycerides, and blood pressure
Time frame: 10 years
Weight loss
Peroperative weight (in kg) minus current weight (in kg)
Time frame: 10 years
BMI loss
Peroperative BMI minus current BMI. Weight and height will be combined to report BMI in kg/m\^2.
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.